Specifically, incrementally reducing the probability of AIDS-related mortality in patients with a history of previous opportunistic infections (attribution) by 25% for CD4 50–199/μl and 50% for CD4 ≥200/μl resulted in better estimation of the empiric survival data (Figure 1, Part C). The gene discussed is CD4; the disease is AIDS.